Pegfilgrastim ANF

Drug Profile

Pegfilgrastim ANF

Alternative Names: ANF-Rho™; PEG G CSF ANF; Pegfilgrastim anti-neutropenic factor; Pegylated recombinant human granulocyte colony stimulating factor

Latest Information Update: 29 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Prolong Pharmaceuticals
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neutropenia

Most Recent Events

  • 22 Jun 2017 Pharmacodynamics and adverse events data from a preclinical trial in Neutropenia were presented at the 22nd Congress of the European Haematology Association (EHA-2017)
  • 21 Dec 2016 Phase-II clinical trials in Neutropenia (Chemotherapy-induced, Prevention) in Netherlands (SC) (EudraCT2016-001965-98)
  • 03 Jun 2016 Pharmacokinetics and pharmacodynamics data from a phase I trial in healthy volunteers presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top